Published in Hepatology on November 30, 2015
The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2(-/-) mice. Hepatology (2017) 0.81
Recent advances in understanding and managing cholestasis. F1000Res (2016) 0.79
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun (2017) 0.76
MitoNEET Deficiency Alleviates Experimental Alcoholic Steatohepatitis in Mice by Stimulating Endocrine Adiponectin-Fgf15 Axis. J Biol Chem (2016) 0.75
Pandora's box opens for cholestatic liver disease. Hepatology (2016) 0.75
Toxic bile and sclerosing cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation? Hepatology (2016) 0.75
Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances. Nat Rev Gastroenterol Hepatol (2017) 0.75
Current and future therapies for inherited cholestatic liver diseases. World J Gastroenterol (2017) 0.75
Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge. Hepatol Int (2016) 0.75
Myeloid Cell-Specific Lipin-1 Deficiency Stimulates Endocrine Adiponectin-FGF15 Axis and Ameliorates Ethanol-Induced Liver Injury in Mice. Sci Rep (2016) 0.75
Hepatitis B virus surface proteins accelerate cholestatic injury and tumor progression in Abcb4-knockout mice. Oncotarget (2017) 0.75
Bile Acid Uptake Transporters as Targets for Therapy. Dig Dis (2017) 0.75
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 9.14
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell (2000) 6.71
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 4.76
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev (2003) 3.74
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 3.33
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology (2002) 3.21
A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet (1998) 3.09
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev (2012) 2.91
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 2.67
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol (2002) 2.55
Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med (1997) 2.41
Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A (1998) 2.17
Identification of a hormonal basis for gallbladder filling. Nat Med (2006) 2.03
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology (2001) 1.99
The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology (2011) 1.94
Primary sclerosing cholangitis. N Engl J Med (1995) 1.94
A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology (2003) 1.90
Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res (2008) 1.74
Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab (2012) 1.67
A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med (2014) 1.64
High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology (2009) 1.62
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology (2001) 1.55
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology (2005) 1.45
Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. Gastroenterology (2015) 1.44
Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet (1999) 1.41
Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet (2000) 1.39
Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest (1995) 1.39
The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis (2010) 1.38
Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A (1999) 1.27
ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology (2008) 1.20
Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem (2003) 1.18
Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology (2004) 1.15
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacol Ther (1994) 1.06
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology (2011) 1.05
Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology (2012) 1.00
Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls. Lipids (2009) 0.98
The Cholangiopathies. Mayo Clin Proc (2015) 0.98
Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci (2013) 0.97
Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum Gene Ther (2009) 0.97
Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology (1998) 0.97
Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet (2007) 0.96
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer (2014) 0.95
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Cancer Res (2014) 0.90
First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis. Eur J Hum Genet (2011) 0.89
Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice. Am J Physiol Gastrointest Liver Physiol (2014) 0.85
Sclerosing cholangitis in children. J Pediatr (1994) 0.83